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Abstract 
Psoriasis is a chronic inflammatory skin disorder; its 
genetic background has been widely studied in recent 
decades. Recognition of novel factors contributing to 
the pathogenesis of this disorder was facilitated by 
potent molecular biology tools developed during the 
1990s. Large-scale gene expression studies, including 
differential display and microarray, have been used in 
experimental dermatology to a great extent; moreover, 
skin was one of the first organs analyzed using these 
methods. We performed our first comprehensive gene 
expression analysis in 2000. With the help of differen-
tial display and microarray, we have discovered several 
novel factors contributing to the inherited susceptibility 
for psoriasis, including the EDA+ fibronectin splice vari-
ant and PRINS. The long non-coding PRINS RNA is ex-
pressed at higher levels in non-involved skin compared 
to healthy and involved psoriatic epidermis and might 
be a factor contributing cellular stress responses and, 
specifically, to the development of psoriatic symptoms. 
This review summarizes the most important results of 
our large-scale gene expression studies.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Large-scale gene expression studies, includ-
ing differential display and microarray, have provided 
valuable data on the molecular background of psoria-
sis pathogenesis. This review summarizes the most 
important results of the available literature and our 
large-scale gene expression studies obtained from the 
clinically non-involved psoriatic skin: we identified the 
EDA+ fibronectin splice variant as an autocrine prolif-
eration signal for psoriatic hyperproliferative keratino-
cytes and PRINS, a long non-coding regulatory RNA. 
We believe that the characterization of new candidate 
genes and proteins might establish new therapeutic 
approaches, which may allow treatment of already ex-
isting psoriatic lesions as well as non-involved psoriatic 
skin by affecting molecular aberrancies, and may lead 
to the development of prophylactic interventions.
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INTRODUCTION
Psoriasis is a hyperproliferative inflammatory skin dis-
order affecting approximately 2%-3% of  the European 
population[1]. However, in some other parts of  the world, 
this disease is almost unknown: e.g., in Africa the occur-
rence of  psoriatic cases is remarkably rare[2]. The exact 
trigger of  the disease is still obscured and the subject of  
several investigations. Inherited and environmental fac-
tors (e.g., mechanical trauma, UV exposure, stress) are re-
sponsible for the development of  psoriatic symptoms[2,3]. 
In the most typical cases, hyperproliferative psoriatic 
plaques are formed on the skin of  the knees, elbows and 
the scalp. In addition, the disorder can affect skin an-
nexes and joints. In the case of  some patients with severe 
psoriasis, the entire body is covered with lesions. Severe 
psoriasis is often associated with metabolic syndrome; 
hence, psoriasis patients also have elevated cardiovascular 
and stroke risks[2]. Unfortunately, psoriasis has a negative 
effect on the patient’s quality of  life due to serious psy-
chosocial and emotional stress[4]. A number of  emerging 
arguments support the idea that psoriasis is a systemic 
disorder rather than simply a skin disease. Psoriasis has 
many common features with chronic autoimmune in-
flammatory disorders, such as progressive arthritis. More-
over, psoriasis and autoimmune syndromes often share 
common genetic loci[5-7]. Similarities are especially evident 
when psoriasis is compared to chronic inflammatory 
bowel disorders, such as Crohn’s disease, where internal 
barriers are involved[8,9]. 
Similarly to autoimmune disorders, immune-activation 
plays an important role in psoriasis: the development of  
the characteristic erythematosus, demarcated and scaly 
lesions is related to the abnormal functioning of  the cel-
lular immune system[10-14]. Cytokines produced by aber-
rantly functioning T-lymphocytes are able to stimulate 
keratinocytes, which show an elevated sensitivity to these 
proliferative signals[14,15]. However, it is still unknown 
whether the primary triggers of  the disease phenotype 
are the professional immune cells or the keratinocytes. 
Inherited susceptibility of  keratinocytes has been par-
tially established. Identification and characterization of  
these factors may greatly facilitate the understanding of  
the molecular background of  psoriasis. Large-scale gene 
expression profiling methods developed and used in 
the 1990s might be useful tools to answer these exciting 
questions.
DAWN OF THE LARGE-SCALE GENE 
EXPRESSION STUDIES: DIFFERENTIAL 
DISPLAY AND SAGE
In recent years, we and others have tried to characterize 
molecular factors responsible for the hyper responsive-
ness of  keratinocytes to various stimuli[8,12,14,16]. To reveal 
these processes, researchers need suitable and powerful 
methods that can detect more than one possible target. 
Previously, altered expression of  only a few candidate 
genes or proteins was possible. The development of  
large-scale gene expression analysis methods marked a 
significant breakthrough in this field. With the help of  
microarrays and their predecessors, differential display 
(DD) and the serial analysis of  gene expression (SAGE), 
gene-expression patterns of  serial samples can be com-
pared for large data sets.
For DD, gene expression profiles are analyzed for 
pairs of  corresponding sample sets. The most important 
steps of  the method are the isolation of  total RNA from 
the samples and its reverse transcription into cDNA. 
Subsequently, cDNA is amplified, subjected to gel elec-
trophoresis and, after the expression pattern has been 
compared, bands representing differentially expressed 
genes are cut out from the gel and the DNA content is 
cloned into a plasmid vector. It should be mentioned that 
the DD method has some limitations due to the relatively 
frequent incidence of  false positive results. Hence, the 
results must be validated using an independent technique. 
Validation is usually carried out by reverse Southern 
blot analysis, followed by sequencing the differentially 
expressed transcripts[17-19]. The great advantage of  DD is 
that it is an “open ended” analysis system, allowing unan-
notated differentially expressed transcripts to be identi-
fied.
Another sequence-based approach, SAGE, was de-
veloped at the Oncology Center of  the Johns Hopkins 
University by Velculescu and his co-workers. Changes 
in gene expression patterns are detected by sequencing 
reverse transcribed cDNAs. Application of  short oligo-
nucleotide sequence tags allows quantitative changes to 
be monitored, in addition to the qualitative analysis[20,21]. 
MICROARRAYS
Microarrays provide more extended and comprehensive 
methods for analyzing gene expression profiles than DD 
and SAGE. The biggest advantage of  this approach is 
that it allows thousands of  genes to be measured simulta-
neously. Moreover, complex regulatory networks can be 
assessed[22,23]. In contrast to DD and SAGE, microarrays 
are a “closed” analysis system, allowing only known se-
quences to be screened. The introduction and widespread 
use of  microarrays has facilitated advances in several 
branches of  science, including experimental dermatology. 
In fact, the skin was one of  the first human organs to be 
analyzed with this technique[24-27].
Microarray technologies rely on complementarity for 
sequence-specific recognition of  the DNA segments[28]. 
Most commonly used probes are cDNAs derived from 
bacterial libraries and BACs or oligonucleotides. Long oli-
gonucleotide probes (50-120 nt) might support a higher 
degree of  specificity and sensitivity than short (15-25 nt) 
probes[22]. The probes are fixed to a solid support, such as 
glass or plastic that are referred to as “chips” in common 
laboratory jargon[23]. 
For microarray experiments, total RNA is isolated 
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from samples and reverse-transcribed with fluorescent 
dyes such as Cy3 and Cy5 or with radioactive isotope to 
label the synthesized cDNA. After hybridizing the labeled 
probes to the chips for approximately 16-24 h, the chips 
are washed and the fluorescence is scanned with a confo-
cal microscopy. Data are then analyzed using specially de-
veloped software. Like DD, this method can identify false 
positives and, therefore, must be validated by RT-PCR, 
northern blot analysis or RNAse protection assay[22,28]. 
The outstanding advantage of  microarray techniques 
is the simultaneous investigation of  thousands of  genes 
and, thus, the possibility to explore novel molecular path-
ways. This technique can be a powerful tool in tumor and 
biomarker research and may serve as the basis of  person-
alized therapies[27].
LARGE-SCALE GENE EXPRESSION 
STUDIES OF PSORIASIS: 
IDENTIFICATION OF MOLECULAR 
FACTORS CONTRIBUTING TO 
PATHOGENESIS
The use of  large-scale gene-expression analysis methods 
has been fruitful for experimental dermatology. Microar-
rays have been used to study several disorders, such as 
melanoma, atopic dermatitis and autoimmune skin dis-
eases. In the past decade, DD and microarray techniques 
have been widely employed alone or in combination with 
other methods in psoriasis research[29]. 
Gene-expression profiling of  peripheral blood cells 
and epidermis samples from healthy, psoriatic involved 
and psoriatic non-involved skin proved to be a powerful 
tool for the characterization of  aberrant molecular pat-
terns in the disease[30]. The results of  cDNA microarrays 
supported previous findings and were useful to describe 
novel pathways implicated in psoriasis pathogenesis. Pso-
riasis research was dominated by the so-called “immune 
theory” for many years, and microarray studies further 
proved the involvement of  genes related to inflammation 
and immune responses. One of  the earliest microarrays 
identified several inflammation- and immune-related 
genes (IL4R, CD2, CD24 and INF-γ induced genes) 
that were not previously reported to contribute to the 
pathogenesis of  this disorder[30,31]. Moreover, Oestreicher 
et al[31] performed a longitudinal analysis in which they 
characterized changes in gene expression in response 
to recombinant human IL-1 or cyclosporine in therapy 
responder and non-responder populations. A study from 
Zhou, which compared samples from healthy, involved 
psoriatic and non-involved psoriatic skin biopsies further 
supported the involvement of  the activated T-cell prod-
uct INF-γ and transcription factors induced by this pro-
inflammatory lymphokine[30,32]. The role of  IL-17 signal-
ing was also demonstrated in large-scale gene-expression 
studies[13]. In addition, Gudjonsson et al[3] emphasized the 
role of  altered innate immune functions in psoriasis. Dif-
ferential expression of  genes encoding chemokines and 
their receptors were also described by several research 
groups[32-34]. 
Other important cellular pathways related to pso-
riasis regulate epidermal keratinocyte proliferation and 
apoptosis. The implication of  PPAR-δ, mTOR, NFκB, 
BCL-2 and BAX expression was verified for these mech-
anisms[35-37]. In a study of  Wnt pathways responsible for 
stem cell proliferation and differentiation, Reischl et al[38] 
found that only Wnt5a expression was higher in psoriatic 
involved skin than in non-involved samples. In addi-
tion, actin cytoskeleton organization can be affected: the 
CCNA2 gene is responsible for the G2/M transition in 
the cell cycle and affects intracellular cytoskeleton organi-
zation and cell migration[39,40].
The clinical association of  psoriasis and metabolic 
syndrome is a well-known phenomenon. Gudjonsson 
and co-workers were able to show that lipid metabolism 
pathways were altered in psoriatic non-involved epider-
mis compared to healthy samples[3]. In this comparison, 
it was proven that lipid metabolism genes were down-
regulated in non-involved skin samples as compared to 
healthy skin and further down-regulation was identified 
in psoriatic involved skin[3]. Romanowska et al[35] studied 
the role of  PPARδ, a transcription factor participating 
in metabolic and inflammatory processes, in psoriasis. 
PPARδ exerts proangiogenic and antiapoptotic affects 
and is suspected to be involved in the enhancement of  
keratinocyte proliferation[35].
Most recently, bioinformatic meta-analyses were per-
formed using publicly available databases of  psoriasis-
related microarray data. In one of  the first microarray 
meta-analysis, Tian et al[41] analyzed the result of  five pre-
vious cDNA microarrays experiments. In a subsequent 
meta-analysis, Manczinger et al[40] compared differentially 
expressed genes of  psoriatic involved and non-involved 
epidermis. The findings of  these two meta-analyses 
agreed and showed that the most important components 
of  the molecular networks related to psoriasis are factors 
implicated in cell proliferation and immunomodulation. 
Importantly, these meta-analyses confirmed that several 
differentially expressed transcripts were also involved in 
metabolic disturbances, such as impaired glucose toler-
ance, insulin tolerance and atherosclerosis[40,41]. 
It is important to note that most of  the large-scale 
gene expression studies for the identification of  mo-
lecular patterns in psoriasis pathogenesis have compared 
the gene expression profiles of  psoriatic involved and 
non-involved skin or psoriatic involved and healthy skin. 
This research provided extremely valuable data for the 
molecular events of  psoriasis[40]. Much less information 
is available, however, on differentially expressed genes in 
normal epidermis compared to psoriatic non-involved 
epidermis. We and others believe that identifying aber-
rantly expressed genes and molecular patterns in non-
involved psoriatic epidermis is important for understand-
ing this disease.
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ratinocyte hyperproliferation in psoriasis[16].
We have also performed in vitro experiments to un-
derstand the role of  EDA+ fibronectin in the regulation 
of  keratinocyte proliferation. Subsequently, RT-PCR was 
carried out using immortalized HaCaT cells. Our results 
indicated that, after serum starvation and contact inhibi-
tion, the highest level of  EDA+ fibronectin expression 
could be detected in the highly proliferative HaCaT cells, 
and the ratio of  EDA+/EDA- fibronectin produced by 
the keratinocytes might well be a potent mitogen signal 
in cell cycle regulation. In contrast to fibroblasts and nor-
mal human keratinocytes, the ratio was altered in this cell 
line. Flow cytometry supported the RT-PCR results. The 
results of  the HaCaT cell line experiments indicated that 
keratinocytes themselves might produce the oncofetal 
fibronectin variant[16].
In addition to proteins with known functions, the DD 
experiment identified a novel transcript: the correspond-
ing gene was subsequently named psoriasis-susceptibility-
related RNA gene induced by stress (PRINS, accession 
number AK022043). During the structural investigation 
of  PRINS, we found that the gene consists of  two exons 
containing several stop codons, which prevent the forma-
tion of  a longer open reading frame. In silico sequence 
comparison supported the hypothesis that PRINS func-
tions as a non-coding RNA molecule, rather than serving 
as a template for protein translation. In addition, PRINS 
contains two repetitive Alu sequences and has 70% se-
quence similarity with the Tetrahymena thermophyla G8 
small nucleolar non-coding RNA[42].
In a quantitative RT-PCR analysis, we demonstrated 
that PRINS is expressed at higher levels in non-involved 
skin compared to healthy and involved psoriatic epider-
mis. Our in vitro experiments performed on synchronized 
HaCaT cells showed that PRINS expression dropped 
significantly when the cells were released from cell quies-
cence and the cells started to proliferate actively[42]. These 
data suggested that PRINS might be a factor disposing 
keratinocytes to hyperproliferation and contributing to 
the development of  psoriatic symptoms. The exact role 
of  PRINS is still unknown, but it is very possible that 
it plays an important role in cellular stress responses. 
Silencing PRINS did not affect the survival of  the cells; 
however under certain stress conditions (such as serum 
starvation) the cells died at a much higher rate when the 
expression of  PRINS was down-regulated[42,51]. Conse-
quently, the PRINS-silenced cells became more vulner-
able, supporting the cellular-stress response hypothesis. 
Moreover, our research group later showed that the 
G1P3 antiapoptotic protein might be regulated by the 
PRINS non-coding RNA[52]. 
Since then, we have identified nucleophosmin as one 
of  the possible cellular interacting partners of  PRINS. 
Nucleophosmin is a phosphoprotein which is a member 
of  the p53 pathway, and its movement in fibroblasts, can-
cer cells and keratinocytes is triggered by ultraviolet (UV) 
exposure[53]. We also demonstrated that silencing PRINS 
prevents nucleolar-cytoplasmic shuttling of  nucleophosmin. 
DIFFERENTIAL DISPLAY AND 
MICROARRAY EXPERIMENTS OF 
OUR RESEARCH GROUP, FOR THE 
IDENTIFICATION OF NOVEL MOLECULAR 
FACTORS OF PSORIASIS
Our research group performed the first comprehensive 
gene-expression analysis for psoriasis in 2000 to compare 
psoriatic non-involved epidermal samples with control 
healthy epidermis. This approach allowed early and inher-
ited molecular factors to be studied in detail and allowed 
novel susceptibility factors to be revealed. This study 
identified two known transcripts that were differentially 
expressed: RAB10, an oncogene that belongs to the small 
GTPase superfamily, and fibronectin, a well-known ex-
tracellular matrix component[42]. Our subsequent studies 
focused on the role of  fibronectin in the pathogenesis of  
psoriasis. 
Fibronectin is a complex glycoprotein composed of  
repetitive modules[43]. At least 24 differentially spliced 
variants of  this gene have been described, and the pres-
ence of  certain variants depends on age, developmental 
state and cell type[44]. Alternative processing involves three 
preferred sites: extra domain A (EDA), extra domain 
B and extra type homology B[43,45]. The splice variants 
containing the EDA domain play a crucial role in embry-
onic development and wound healing. However they are 
detectable only in modest amounts in adult normal tis-
sues[44,46,47]. Because it is also abundantly expressed in dif-
ferent types of  tumors, it is referred to as the oncofetal 
fibronectin splice variant[48]. Interestingly, in the brain, an 
organ in which fibronectin is poorly expressed, the inclu-
sion of  the EDA domain is abundant in young adults 
(88% as compared to fetal level) and decreases with age 
to 33%[46].
The presence of  the EDA+ fibronectin variant is 
associated with several pathological conditions and is 
suspected to participate in the development of  psoriasis 
as well. The oncofetal fibronectin form was found to be 
present in a higher ratio at the dermal-epidermal junc-
tion of  psoriatic non-involved skin compared to healthy 
normal skin[14,49]. Unlike the conventional variant, the 
oncofetal EDA+ fibronectin form interacts with the α5 
integrin subtype, instead of  α2 and α3, and, as a result, 
its effect on cellular signaling processes is more robust. 
α5β1 integrin receptors were shown to be upregulated in 
both non-involved and involved psoriatic skin[14,50]. 
In addition, other authors reported that the EDA+ 
fibronectin variant is co-localized with CD11c+ macro-
phages. It was suggested that these cells might contribute 
to the production of  the oncofetal variant; however, be-
cause of  their relatively low number, they are likely not to 
be the most important source[49]. Based on our results we 
supposed that keratinocytes themselves might produce 
EDA+ fibronectin and, as an autocrine molecular factor, 
may contribute to the induction and maintenance of  ke-
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This result indicates that PRINS might physically interact 
with the nucleophosmin protein and that the abnormal 
functioning of  the PRINS-nucleophosmin ribonucleopro-
tein complex may contribute to psoriasis pathogenesis[54].
Taken together, we consider the identification of  nov-
el factors implicated in the early molecular defects in pso-
riasis pathogenesis-the EDA+ fibronectin splice-variant 
and the PRINS non-coding RNA-the most significant 
outcomes of  our DD experiments. Due to the success 
of  the DD, we attempted to identify novel psoriasis sus-
ceptibility factors using newly available cDNA microarray 
technology for large-scale gene-expression analysis. In 
particular, we aimed to identify molecular patterns that 
are responsible for the differential reactivity of  normal 
healthy epidermis and psoriatic non-involved epidermis.
Organotypic tissue cultures were created from four 
healthy and four psoriatic non-involved skin samples. 
Half  of  the samples were treated with a mixture of  T-cell 
lymphokines, containing IL-3, IFNγ and GM-CSF, cyto-
kines previously described to be implicated in the T-cell 
response and the formation of  psoriatic plaques[10]. After 
three days of  treatment, the dermis and epidermis were 
separated. Total RNA was isolated from the epidermis, 
reverse transcribed and used to perform the cDNA mi-
croarray experiment. Based on the results, we selected 
genes that showed an altered gene expression in response 
to the lymphokine treatment[12]. 
We identified 61 transcripts that exhibited altered gene 
expression. Of  these, eleven had been demonstrated ear-
lier to contribute to psoriasis. Using bioinformatics tools, 
such as Gene Ontology and Ingenuity pathway analysis, 
we demonstrated that most of  these molecules are impli-
cated in two important intracellular pathways: “apoptosis” 
and “metabolism of  small molecules and lipids.” Real-
time RT-PCR validation experiments revealed that many 
of  these genes are already upregulated in non-involved 
psoriatic epidermis, and the lymphokine treatment did 
not further increase expression. In contrast, expression 
of  these genes was inducible in healthy samples. These 
data indicate that keratinocytes in psoriatic non-involved 
epidermis are in a presensitised status, which explains 
their altered response to different triggering stimuli[12].
Among the differentially expressed genes, we also 
identified members of  the serine-arginine rich (SR) 
proteins SR splicing factor 18 (SFRS18), peptidylprolyl 
isomerase G (PPIG) and luc-7 like 3 (LUC7L3), which 
regulate mRNA splicing. It was previously described that 
these proteins interact with pinin and SR-related nuclear 
protein[55-60]. Splicing is a post-transcriptional regula-
tory process and one of  the most important sources of  
mRNA diversity, permitting the production of  different 
mRNAs from the same DNA template. Splicing dysfunc-
tion has been shown to be involved in several disorders, 
and some novel therapeutic modalities have been de-
signed to repair them[61-63].
Our research group has previously demonstrated that 
the fibronectin splice variants containing the EDA do-
main is implicated in the pathogenesis of  psoriasis. This 
suggests the interesting question whether the identified 
splicing genes, LUC7L3, PPIG and SFRS18, contribute 
to the production of  the EDA+ fibronectin variant. We 
are currently investigating the role of  LUC7L3, PPIG 
and SFRS18 splicing regulatory genes in the production 
of  EDA+ fibronectin, and we aim to identify further dif-
ferentially spliced mRNA variants contributing to psoria-
sis pathogenesis. 
CONCLUSION
Taken together, recent comparisons between psoriatic 
non-involved and involved epidermis dominated large-
scale gene expression studies related to psoriasis. Rela-
tively few studies have focused on the comparison of  
gene expression differences between healthy and psoriatic 
non-involved epidermis samples. Nonetheless, we believe 
that these experiments are valuable for identifying factors 
that increase the risk for developing psoriatic plaques. In 
our microarray studies, we identified several novel candi-
date genes and molecular patterns that might contribute 
the formation of  typical lesions. The altered expression 
of  EDA+ fibronectin and that of  LUC7L3, PPIG and 
SFRS-18 suggests that some kind of  splicing anomalies 
have an important role in the development of  psoriatic 
symptoms. The exploration of  cellular networks related 
to RNA-maturation processes gave us a deeper insight 
into the molecular pathogenesis of  psoriasis and investi-
gation of  the splicing machinery might be a very new ap-
proach in this field. Results of  wide-scale gene expression 
studies have provided pioneering advances in psoriasis 
research as well as in the recognition of  different types 
of  non-coding RNAs, including PRINS. This RNA is 
a long non-coding RNA (lncRNA), and most lncRNAs 
have been identified in their involvements in the central 
nervous system and certain tumors[64-69].
The last decade has seen a rapid evolution in large-
scale gene expression profiling methods. Techniques, 
such as RNA-Seq and digital gene expression profiling, 
provide an even greater resolution and wider dynamic 
range compared to either DD or cDNA microarray. 
Advancement of  methods based on next-generation se-
quencing has accelerated the accumulation of  data, and 
processing the results requires huge efforts. Thus, valida-
tion and interpretation of  these newly discovered fac-
tors is a very important challenge. Identification of  new 
candidates might establish new therapeutic approaches, 
which may allow treatment of  already existing psoriatic 
lesions as well as non-involved psoriatic skin by affecting 
molecular aberrancies, and may lead to the development 
of  prophylactic interventions.
REFERENCES
1 Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 
2009; 361: 496-509 [PMID: 19641206 DOI: 10.1056/NEJM-
ra0804595]
2 Roberson ED, Bowcock AM. Psoriasis genetics: breaking 
the barrier. Trends Genet 2010; 26: 415-423 [PMID: 20692714 
54
Szlavicz E et al . Aberrant molecular patterns in psoriatic non-involved skin
August 2, 2014|Volume 3|Issue 3|WJD|www.wjgnet.com
DOI: 10.1016/j.tig.2010.06.006]
3 Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS, 
Ghosh D, Aphale A, Gumucio DL, Voorhees JJ, Abeca-
sis GR, Elder JT. Global gene expression analysis reveals 
evidence for decreased lipid biosynthesis and increased 
innate immunity in uninvolved psoriatic skin. J Invest Der-
matol 2009; 129: 2795-2804 [PMID: 19571819 DOI: 10.1038/
jid.2009.173]
4 Hunter HJ, Griffiths CE, Kleyn CE. Does psychosocial stress 
play a role in the exacerbation of psoriasis? Br J Dermatol 
2013; 169: 965-974 [PMID: 23796214 DOI: 10.1111/bjd.12478]
5 Bowcock AM, Barker JN. Genetics of psoriasis: the potential 
impact on new therapies. J Am Acad Dermatol 2003; 49: S51-S56 
[PMID: 12894126 DOI: 10.1016/S0190-9622(03)01135-6]
6 Bowcock AM. Psoriasis genetics: the way forward. J Invest 
Dermatol 2004; 122: xv-xvii [PMID: 15175054 DOI: 10.1111/
j.0022-202X.2004.22627.x]
7 Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon 
F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, Kang HM, Allen 
MH, McManus R, Novelli G, Samuelsson L, Schalkwijk 
J, Ståhle M, Burden AD, Smith CH, Cork MJ, Estivill X, 
Bowcock AM, Krueger GG, Weger W, Worthington J, Tazi-
Ahnini R, Nestle FO, Hayday A, Hoffmann P, Winkelmann J, 
Wijmenga C, Langford C, Edkins S, Andrews R, Blackburn 
H, Strange A, Band G, Pearson RD, Vukcevic D, Spencer 
CC, Deloukas P, Mrowietz U, Schreiber S, Weidinger S, 
Koks S, Kingo K, Esko T, Metspalu A, Lim HW, Voorhees 
JJ, Weichenthal M, Wichmann HE, Chandran V, Rosen CF, 
Rahman P, Gladman DD, Griffiths CE, Reis A, Kere J, Nair 
RP, Franke A, Barker JN, Abecasis GR, Elder JT, Trembath 
RC. Identification of 15 new psoriasis susceptibility loci 
highlights the role of innate immunity. Nat Genet 2012; 44: 
1341-1348 [PMID: 23143594 DOI: 10.1038/ng.2467]
8 Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut 
K, Catier J, Fernandez-Vina MA, Menter A. Insights into 
psoriasis and other inflammatory diseases from large-scale 
gene expression studies. Hum Mol Genet 2001; 10: 1793-1805 
[PMID: 11532989 DOI: 10.1093/hmg/10.17.1793]
9 Képíró L, Széll M, Kovács L, Keszthelyi P, Kemény L, Gyu-
lai R. Genetic risk and protective factors of TNFSF15 gene 
variants detected using single nucleotide polymorphisms 
in Hungarians with psoriasis and psoriatic arthritis. Hum 
Immunol 2014; 75: 159-162 [PMID: 24269700 DOI: 10.1016/
j.humimm.2013.11.006]
10 Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. 
Kinetics and regulation of human keratinocyte stem cell 
growth in short-term primary ex vivo culture. Cooperative 
growth factors from psoriatic lesional T lymphocytes stimu-
late proliferation among psoriatic uninvolved, but not nor-
mal, stem keratinocytes. J Clin Invest 1995; 95: 317-327 [PMID: 
7529261 DOI: 10.1172/JCI117659]
11 Bos JD, De Rie MA. The pathogenesis of psoriasis: immuno-
logical facts and speculations. Immunol Today 1999; 20: 40-46 
[PMID: 10081229 DOI: 10.1016/S0167-5699(98)01381-4]
12 Szabó K, Bata-Csörgő Z, Dallos A, Bebes A, Francziszti L, 
Dobozy A, Kemény L, Széll M. Regulatory Networks Con-
tributing to Psoriasis Susceptibility. Acta Derm Venereol 2014 
Epub ahead of print [DOI: 10.2340/00015555-1708]
13 Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, 
Novitskaya I, Pierson KC, Gonzalez J, Krueger JG, Lowes 
MA. Psoriasis is characterized by accumulation of immuno-
stimulatory and Th1/Th17 cell-polarizing myeloid dendritic 
cells. J Invest Dermatol 2009; 129: 79-88 [PMID: 18633443 
DOI: 10.1038/jid.2008.194]
14 Bata-Csorgo Z, Cooper KD, Ting KM, Voorhees JJ, Ham-
merberg C. Fibronectin and alpha5 integrin regulate kerati-
nocyte cell cycling. A mechanism for increased fibronectin 
potentiation of T cell lymphokine-driven keratinocyte 
hyperproliferation in psoriasis. J Clin Invest 1998; 101: 
1509-1518 [PMID: 9525994 DOI: 10.1172/JCI171]
15 McFadden JP, Basketter DA, Dearman RJ, Kimber IR. Extra 
domain A-positive fibronectin-positive feedback loops and 
their association with cutaneous inflammatory disease. Clin 
Dermatol 2011; 29: 257-265 [PMID: 21496732 DOI: 10.1016/
j.clindermatol.2010.11.003]
16 Széll M, Bata-Csörgo Z, Koreck A, Pivarcsi A, Polyánka H, 
Szeg C, Gaál M, Dobozy A, Kemény L. Proliferating kerati-
nocytes are putative sources of the psoriasis susceptibility-
related EDA+ (extra domain A of fibronectin) oncofetal 
fibronectin. J Invest Dermatol 2004; 123: 537-546 [PMID: 
15304094 DOI: 10.1111/j.0022-202X.2004.23224.x]
17 Laskowski MJ. RNA differential display. In: Plant Molecu-
lar Biology Manual. In: Gelvin SB, Schilperoort RA, editors. 
Netherlands: Springer Netherlands, 1997: 33-52 [DOI: 10.100
7/978-94-011-5400-0_3]
18 Liang P, Pardee AB. Differential display. A general proto-
col. Mol Biotechnol 1998; 10: 261-267 [PMID: 9951706 DOI: 
10.1007/BF02740847]
19 Liang P. A decade of differential display. Biotechniques 2002; 
33: 338-344, 346 [PMID: 12188186]
20 Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial 
analysis of gene expression. Science 1995; 270: 484-487 [PMID: 
7570003 DOI: 10.1126/science.270.5235.484]
21 Madden SL, Wang CJ, Landes G. Serial analysis of gene ex-
pression: from gene discovery to target identification. Drug 
Discov Today 2000; 5: 415-425 [PMID: 10931659]
22 Villaseñor-Park J, Ortega-Loayza AG. Microarray tech-
nique, analysis, and applications in dermatology. J Invest 
Dermatol 2013; 133: e7 [PMID: 23486432 DOI: 10.1038/
jid.2013.64]
23 Kunz M, Ibrahim SM, Koczan D, Scheid S, Thiesen HJ, 
Gross G. DNA microarray technology and its applications 
in dermatology. Exp Dermatol 2004; 13: 593-606 [PMID: 
15447719 DOI: 10.1111/j.0906-6705.2004.00243.x]
24 Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, 
Trent JM, Staudt LM, Hudson J, Boguski MS, Lashkari 
D, Shalon D, Botstein D, Brown PO. The transcriptional 
program in the response of human fibroblasts to serum. 
Science 1999; 283: 83-87 [PMID: 9872747 DOI: 10.1126/sci-
ence.283.5398.83]
25 Robbins PB, Sheu SM, Goodnough JB, Khavari PA. Impact 
of laminin 5 beta3 gene versus protein replacement on gene 
expression patterns in junctional epidermolysis bullosa. 
Hum Gene Ther 2001; 12: 1443-1448 [PMID: 11485635 DOI: 
10.1089/104303401750298599]
26 Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA. Di-
vergent gene regulation and growth effects by NF-kappa 
B in epithelial and mesenchymal cells of human skin. On-
cogene 2003; 22: 1955-1964 [PMID: 12673201 DOI: 10.1038/
sj.onc.1206198]
27 Blumenberg M. SKINOMICS: Transcriptional Profiling 
in Dermatology and Skin Biology. Curr Genomics 2012; 13: 
363-368 [PMID: 23372422 DOI: 10.2174/13892021280161924
1]
28 Sellheyer K, Belbin TJ. DNA microarrays: from structural 
genomics to functional genomics. The applications of gene 
chips in dermatology and dermatopathology. J Am Acad 
Dermatol 2004; 51: 681-692; quiz 693-696 [PMID: 15523345 
DOI: 10.1016/j.jaad.2004.03.038]
29 Blumenberg M. DNA microarrays in dermatology and skin 
biology. OMICS 2006; 10: 243-260 [PMID: 17069506 DOI: 
10.1089/omi.2006.10.243]
30 Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaff-
ney PM, Moser KL, Gregersen PK, Behrens TW. Gene 
expression profiling in human autoimmunity. Immunol 
Rev 2006; 210: 120-137 [PMID: 16623768 DOI: 10.1111/
j.0105-2896.2006.00367.x]
31 Oestreicher JL, Walters IB, Kikuchi T, Gilleaudeau P, 
Surette J, Schwertschlag U, Dorner AJ, Krueger JG, Trepic-
chio WL. Molecular classification of psoriasis disease-associ-
55
Szlavicz E et al . Aberrant molecular patterns in psoriatic non-involved skin
August 2, 2014|Volume 3|Issue 3|WJD|www.wjgnet.com
ated genes through pharmacogenomic expression profiling. 
Pharmacogenomics J 2001; 1: 272-287 [PMID: 11911124 DOI: 
10.1038/sj.tpj.6500067]
32 Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, Wong 
WH, Bowcock AM. Novel mechanisms of T-cell and den-
dritic cell activation revealed by profiling of psoriasis on the 
63,100-element oligonucleotide array. Physiol Genomics 2003; 
13: 69-78 [PMID: 12644634 DOI: 10.1152/physiolgenom-
ics.00157.2002]
33 Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Johnson-
Huang LM, Nograles KE, White TR, Pierson KC, Lentini T, 
Suárez-Fariñas M, Lowes MA, Krueger JG. Identification 
of TNF-related apoptosis-inducing ligand and other mol-
ecules that distinguish inflammatory from resident den-
dritic cells in patients with psoriasis. J Allergy Clin Immunol 
2010; 125: 1261-1268.e9 [PMID: 20471070 DOI: 10.1016/
j.jaci.2010.03.018]
34 Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, 
Leung DY. Distinct patterns of gene expression in the skin 
lesions of atopic dermatitis and psoriasis: a gene microarray 
analysis. J Allergy Clin Immunol 2003; 112: 1195-1202 [PMID: 
14657882 DOI: 10.1016/j.jaci.2003.08.049]
35 Romanowska M, al Yacoub N, Seidel H, Donandt S, Gerken 
H, Phillip S, Haritonova N, Artuc M, Schweiger S, Sterry W, 
Foerster J. PPARdelta enhances keratinocyte proliferation 
in psoriasis and induces heparin-binding EGF-like growth 
factor. J Invest Dermatol 2008; 128: 110-124 [PMID: 17637826 
DOI: 10.1038/sj.jid.5700943]
36 Buerger C, Malisiewicz B, Eiser A, Hardt K, Boehncke WH. 
Mammalian target of rapamycin and its downstream signal-
ling components are activated in psoriatic skin. Br J Dermatol 
2013; 169: 156-159 [PMID: 23398394 DOI: 10.1111/bjd.12271]
37 Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. 
NF-κB: an essential transcription factor in psoriasis. J Der-
matol Sci 2013; 69: 89-94 [PMID: 23219896 DOI: 10.1016/
j.jdermsci.2012.11.002]
38 Reischl J, Schwenke S, Beekman JM, Mrowietz U, Stürze-
becher S, Heubach JF. Increased expression of Wnt5a in 
psoriatic plaques. J Invest Dermatol 2007; 127: 163-169 [PMID: 
16858420 DOI: 10.1038/sj.jid.5700488]
39 Choi JH, Choi DK, Sohn KC, Kwak SS, Suk J, Lim JS, Shin 
I, Kim SW, Lee JH, Joe CO. Absence of a human DnaJ 
protein hTid-1S correlates with aberrant actin cytoskel-
eton organization in lesional psoriatic skin. J Biol Chem 
2012; 287: 25954-25963 [PMID: 22692211 DOI: 10.1074/jbc.
M111.313809]
40 Manczinger M, Kemény L. Novel factors in the pathogen-
esis of psoriasis and potential drug candidates are found 
with systems biology approach. PLoS One 2013; 8: e80751 
[PMID: 24303025 DOI: 10.1371/journal.pone.0080751]
41 Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes 
MA, Suárez-Fariñas M. Meta-analysis derived (MAD) tran-
scriptome of psoriasis defines the “core” pathogenesis of 
disease. PLoS One 2012; 7: e44274 [PMID: 22957057 DOI: 
10.1371/journal.pone.0044274]
42 Sonkoly E, Bata-Csorgo Z, Pivarcsi A, Polyanka H, Ken-
deressy-Szabo A, Molnar G, Szentpali K, Bari L, Megyeri 
K, Mandi Y, Dobozy A, Kemeny L, Szell M. Identification 
and characterization of a novel, psoriasis susceptibility-
related noncoding RNA gene, PRINS. J Biol Chem 2005; 280: 
24159-24167 [PMID: 15855153 DOI: 10.1074/jbc.M501704200]
43 Mecham RP. Overview of extracellular matrix. Curr Protoc 
Cell Biol 2001; Chapter 10: Unit 10.1 [PMID: 18228295 DOI: 
10.1007/978-3-642-16555-9]
44 Muro AF, Chauhan AK, Gajovic S, Iaconcig A, Porro F, 
Stanta G, Baralle FE. Regulated splicing of the fibronec-
tin EDA exon is essential for proper skin wound healing 
and normal lifespan. J Cell Biol 2003; 162: 149-160 [PMID: 
12847088 DOI: 10.1083/jcb.200212079]
45 White ES, Baralle FE, Muro AF. New insights into form and 
function of fibronectin splice variants. J Pathol 2008; 216: 
1-14 [PMID: 18680111 DOI: 10.1002/path.2388]
46 Kornblihtt AR, Pesce CG, Alonso CR, Cramer P, Srebrow 
A, Werbajh S, Muro AF. The fibronectin gene as a model for 
splicing and transcription studies. FASEB J 1996; 10: 248-257 
[PMID: 8641558]
47 White ES, Muro AF. Fibronectin splice variants: under-
standing their multiple roles in health and disease using en-
gineered mouse models. IUBMB Life 2011; 63: 538-546 [PMID: 
21698758 DOI: 10.1002/iub.493]
48 Lohi J, Tani T, Laitinen L, Kangas L, Lehto VP, Virtanen 
I. Tenascin and fibronectin isoforms in human renal cell 
carcinomas, renal cell carcinoma cell lines and xenografts 
in nude mice. Int J Cancer 1995; 63: 442-449 [PMID: 7591246 
DOI: 10.1007/BF02331434]
49 Ting KM, Rothaupt D, McCormick TS, Hammerberg C, 
Chen G, Gilliam AC, Stevens S, Culp L, Cooper KD. Over-
expression of the oncofetal Fn variant containing the EDA 
splice-in segment in the dermal-epidermal junction of pso-
riatic uninvolved skin. J Invest Dermatol 2000; 114: 706-711 
[PMID: 10733677 DOI: 10.1046/j.1523-1747.2000.00871.x]
50 Pellegrini G, De Luca M, Orecchia G, Balzac F, Cremona O, 
Savoia P, Cancedda R, Marchisio PC. Expression, topogra-
phy, and function of integrin receptors are severely altered 
in keratinocytes from involved and uninvolved psoriatic 
skin. J Clin Invest 1992; 89: 1783-1795 [PMID: 1534817 DOI: 
10.1172/JCI115782]
51 Bari L, Bacsa S, Sonkoly E, Bata-Csörgo Z, Kemény L, Dobo-
zy A, Széll M. Comparison of stress-induced PRINS gene 
expression in normal human keratinocytes and HaCaT cells. 
Arch Dermatol Res 2011; 303: 745-752 [PMID: 21750967 DOI: 
10.1007/s00403-011-1162-8]
52 Szegedi K, Sonkoly E, Nagy N, Németh IB, Bata-Csörgo Z, 
Kemény L, Dobozy A, Széll M. The anti-apoptotic protein 
G1P3 is overexpressed in psoriasis and regulated by the 
non-coding RNA, PRINS. Exp Dermatol 2010; 19: 269-278 
[PMID: 20377629 DOI: 10.1111/j.1600-0625.2010.01066.x]
53 Kurki S, Peltonen K, Laiho M. Nucleophosmin, HDM2 
and p53: players in UV damage incited nucleolar stress 
response. Cell Cycle 2004; 3: 976-979 [PMID: 15254398 DOI: 
10.4161/cc.3.8.1015]
54 Szegedi K, Göblös A, Bacsa S, Antal M, Németh IB, Bata-
Csörgő Z, Kemény L, Dobozy A, Széll M. Expression and 
Functional Studies on the Noncoding RNA, PRINS. Int J 
Mol Sci 2012; 14: 205-225 [PMID: 23344029 DOI: 10.3390/
ijms14010205]
55 Lin CL, Leu S, Lu MC, Ouyang P. Over-expression of SR-
cyclophilin, an interaction partner of nuclear pinin, releases 
SR family splicing factors from nuclear speckles. Biochem 
Biophys Res Commun 2004; 321: 638-647 [PMID: 15358154 
DOI: 10.1016/j.bbrc.2004.07.013]
56 Bourquin JP, Stagljar I, Meier P, Moosmann P, Silke J, 
Baechi T, Georgiev O, Schaffner W. A serine/arginine-rich 
nuclear matrix cyclophilin interacts with the C-terminal 
domain of RNA polymerase II. Nucleic Acids Res 1997; 25: 
2055-2061 [PMID: 9153302 DOI: 10.1093/nar/25.11.2055]
57 Hegele A, Kamburov A, Grossmann A, Sourlis C, Wowro 
S, Weimann M, Will CL, Pena V, Lührmann R, Stelzl U. Dy-
namic protein-protein interaction wiring of the human spli-
ceosome. Mol Cell 2012; 45: 567-580 [PMID: 22365833 DOI: 
10.1016/j.molcel.2011.12.034]
58 Puig O, Bragado-Nilsson E, Koski T, Séraphin B. The U1 
snRNP-associated factor Luc7p affects 5’ splice site selection 
in yeast and human. Nucleic Acids Res 2007; 35: 5874-5885 
[PMID: 17726058 DOI: 10.1093/nar/gkm505]
59 Sakashita E, Tatsumi S, Werner D, Endo H, Mayeda A. Hu-
man RNPS1 and its associated factors: a versatile alternative 
pre-mRNA splicing regulator in vivo. Mol Cell Biol 2004; 24: 
1174-1187 [PMID: 14729963 DOI: 10.1128/MCB.24.3.1174]
60 Zimowska G, Shi J, Munguba G, Jackson MR, Alpatov R, 
56
Szlavicz E et al . Aberrant molecular patterns in psoriatic non-involved skin
August 2, 2014|Volume 3|Issue 3|WJD|www.wjgnet.com
Simmons MN, Shi Y, Sugrue SP. Pinin/DRS/memA inter-
acts with SRp75, SRm300 and SRrp130 in corneal epithelial 
cells. Invest Ophthalmol Vis Sci 2003; 44: 4715-4723 [PMID: 
14578391 DOI: 10.1167/iovs.03-0240]
61 Pagani F, Baralle FE. Analysis of Human Splicing Defects 
Using Hybrid Minigenes. Molecular Diagnostics. Trieste, 
Italy: International Centre for Genetic Engineering and 
Biotechnology, Padriciano 99, 2010: 155-169 [DOI: 10.1016/
B978-0-12-374537-8.00011-0]
62 Faustino NA, Cooper TA. Pre-mRNA splicing and human 
disease. Genes Dev 2003; 17: 419-437 [PMID: 12600935 DOI: 
10.1101/gad.1048803]
63 Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol 
2010; 220: 152-163 [PMID: 19918805 DOI: 10.1002/path.2649]
64 Martignetti JA, Brosius J. BC200 RNA: a neural RNA 
polymerase III product encoded by a monomeric Alu ele-
ment. Proc Natl Acad Sci USA 1993; 90: 11563-11567 [PMID: 
8265590 DOI: 10.1073/pnas.90.24.11563]
65 Mus E, Hof PR, Tiedge H. Dendritic BC200 RNA in aging 
and in Alzheimer’s disease. Proc Natl Acad Sci USA 2007; 104: 
10679-10684 [PMID: 17553964 DOI: 10.1073/pnas.0701532104]
66 Széll M, Bata-Csörgo Z, Kemény L. The enigmatic world of 
mRNA-like ncRNAs: their role in human evolution and in 
human diseases. Semin Cancer Biol 2008; 18: 141-148 [PMID: 
18282717 DOI: 10.1016/j.semcancer.2008.01.007]
67 Pollard KS, Salama SR, Lambert N, Lambot MA, Coppens S, 
Pedersen JS, Katzman S, King B, Onodera C, Siepel A, Kern 
AD, Dehay C, Igel H, Ares M, Vanderhaeghen P, Haussler 
D. An RNA gene expressed during cortical development 
evolved rapidly in humans. Nature 2006; 443: 167-172 [PMID: 
16915236 DOI: 10.1038/nature05113]
68 Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis 
L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard 
GS, Mostofi FK, McLeod DG, Moul JW, Srivastava S. PC-
GEM1, a prostate-specific gene, is overexpressed in prostate 
cancer. Proc Natl Acad Sci USA 2000; 97: 12216-12221 [PMID: 
11050243 DOI: 10.1073/pnas.97.22.12216]
69 Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, 
Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. 
DD3: a new prostate-specific gene, highly overexpressed 
in prostate cancer. Cancer Res 1999; 59: 5975-5979 [PMID: 
10606244]
P- Reviewer: Husein-ElAhmed H, Kita K, Lonchin S 
S- Editor: Song XX    L- Editor: A    E- Editor: Lu YJ
57
Szlavicz E et al . Aberrant molecular patterns in psoriatic non-involved skin
                                      © 2014 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
